Schedule H, H1, X — Pharma Marketing Boundaries India 2026 | ICG

Author: ICG Editorial (Pharma Practice) · July 2026

India's drug scheduling system — Schedules H, H1, and X under the Drugs and Cosmetics Act 1940 — determines which drugs require a prescription, which require a specialised prescription, and which are subject to the most stringent controls. For pharma marketers, these schedules determine who can be marketed to, through which channels, and with what content.

The scheduling framework explained

Schedule H drugs: Prescription-only medicines (POM). Dispensed only on the prescription of a registered medical practitioner. Labelled "Rx — For Sale on Prescription of a Registered Medical Practitioner Only."

Marketing implication: Schedule H drugs cannot be advertised to the general public. HCP-directed marketing (through Medical Representatives, CLM presentations, digital engagement platforms) is permitted within the UCPMP 2024 framework. Patient-facing communications about Schedule H drugs must be educational (disease awareness) rather than promotional (drug-specific efficacy claims).

Schedule H1 drugs: A subset of Schedule H with additional controls — schedule-specific drugs with higher misuse or abuse potential. Includes second-line antibiotic combinations, certain antipsychotics, and specific hormonal drugs. Requires prescription with additional record-keeping.

Marketing implication: Schedule H1 drugs face the same public advertising restriction as Schedule H, with additional internal documentation requirements for the dispensing pharmacist. HCP marketing for H1 drugs follows the same UCPMP 2024 framework but with heightened pharmacovigilance documentation requirements.

Schedule X drugs: The most tightly controlled drug category. Psychotropic substances and drugs with significant abuse potential (benzodiazepines, opioids, certain stimulants). Prescription must be in duplicate, with records maintained for 2 years.

Marketing implication: Schedule X drugs can only be marketed to registered medical practitioners (HCP-only). Any form of public-facing promotion for Schedule X drugs is prohibited. UCPMP 2024's HCP engagement standards apply to all Schedule X marketing interactions.

OTC drugs and marketing freedoms

Drugs not listed in Schedule H, H1, or X may be marketed to the general public — subject to:

Schedule J restrictions: If the OTC drug treats a Schedule J listed condition (cancer, diabetes, heart disease, etc.), public advertising of the drug is still prohibited under Schedule J, regardless of the drug's prescription status.

FSSAI standards: For nutraceuticals and health supplements that may contain drug-like active ingredients, FSSAI's advertising standards apply.

Drugs and Magic Remedies Act (DMRA): Prohibits magic remedy claims, misleading efficacy claims, and certain disease treatment claims in drug advertising.

NMC Section 6: If a registered medical practitioner endorses an OTC drug in advertising, Section 6's provisions apply to the endorsement.

UCPMP 2024 and Schedule H/H1/X interaction

UCPMP 2024 governs HCP-directed promotion for all prescription drugs — including Schedule H, H1, and X. The key UCPMP provisions for these schedules:

Evidence standard: All promotional claims about Schedule H/H1/X drugs must be supported by peer-reviewed published evidence, cited in the promotional material.

Off-label promotion prohibition: Marketing or promotional communication suggesting use of a Schedule H/H1/X drug outside its CDSCO-approved indication is prohibited. This is a particularly sensitive area for Schedule H1 antibiotics, where off-label combination use is common clinically but cannot be promoted.

Gift cap (UCPMP 2024): ₹5,000 per HCP per year aggregate limit on non-branded promotional items. Cash, vouchers, or equivalent gifts to HCPs for prescribing Schedule H/H1/X drugs are absolutely prohibited and can trigger NPPA enforcement action.

Pharmacovigilance integration: All HCP engagement channels for Schedule H/H1/X drugs must include an adverse event reporting pathway — patients and HCPs must have an accessible route to report adverse drug reactions. ICG's Pharos Vigil platform provides this for pharma clients.

The pharma content marketing framework for scheduled drugs

ICG's pharma content approach for Schedule H/H1/X drug brands:

Patient-facing content (all scheduled drugs): Disease awareness only. No drug-specific efficacy claims. Service framing for treatment ("our [condition] management programme") rather than drug framing. Schedule J conditions require service framing; non-Schedule J conditions require service framing plus the statement that treatment decisions should be made with a registered medical practitioner.

HCP-facing content (all scheduled drugs): Evidence-based promotional content within UCPMP 2024 framework. CDSCO-approved indication only. ICG's Pharos Gate platform ensures HCP-only content is only accessible to verified registered medical practitioners — preventing Schedule H/H1/X drug-claim content from reaching general public audiences.

Medical affairs content: Non-promotional disease education, clinical evidence dissemination, pharmacovigilance reporting — managed through Pharos Scribe and Pharos Deploy.

FAQ

Q1: Can I advertise a Schedule H drug on a doctor-only LinkedIn post? LinkedIn is not a controlled-access HCP environment — any LinkedIn user can see a post, regardless of whether the poster intends it for HCP audiences. Posting Schedule H promotional content on LinkedIn (even with "for healthcare professionals only" in the caption) is risky because the content is publicly accessible. ICG recommends using Pharos Gate (verified HCP access) for Schedule H promotional content, not open social media platforms.

Q2: How does Schedule J interact with Schedule H for drugs like antihypertensives? A drug that is both Schedule H (prescription-only) and Schedule J-adjacent (treats hypertension, a Schedule J condition) faces dual restrictions: it cannot be marketed to the public as a prescription drug (Schedule H), AND it cannot be advertised as treating hypertension to the public (Schedule J). The result: no patient-facing promotional communication about the drug's therapeutic use. HCP-directed marketing through UCPMP 2024 channels remains permitted.

Q3: Does UCPMP 2024 apply to Indian pharma companies that only sell OTC drugs? UCPMP 2024 primarily governs prescription (Rx) drug marketing — specifically, HCP-directed promotion for Schedule H/H1/X drugs. For OTC-only pharma companies, UCPMP applies when the company engages HCPs as recommenders (doctors who recommend OTC supplements, for example), but general consumer advertising for OTC drugs falls under different regulatory frameworks (FSSAI, DMRA, ASCI Code).

Compliance note: Reviewed against Schedule H/H1/X provisions of D&C Act, UCPMP 2024, Schedule J, FSSAI Advertising Regulations. For pharma enquiries: WhatsApp ICG on 918130226224.